iBio Announces Participation in the H.C. Wainwright BioConnect Conference
January 04, 2022 16:30 ET
|
iBio, Inc.
BRYAN, Texas, Jan. 04, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based...
iBio Announces Partial Adjournment of Annual Meeting of Shareholders to January 31, 2022
December 22, 2021 09:25 ET
|
iBio, Inc.
BRYAN, Texas, Dec. 22, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable,...
iBio Provides Information for Listening to the Virtual Annual Stockholder Meeting
December 21, 2021 09:20 ET
|
iBio, Inc.
BRYAN, Texas, Dec. 21, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable,...
iBio Announces Partial Adjournment of Annual Meeting to December 22
December 10, 2021 08:30 ET
|
iBio, Inc.
- Shareholders Presently Supporting Reverse Split and Authorized Share Proposals by a 2-to-1 Margin - BRYAN, Texas, Dec. 10, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the...
ISS Joins Glass Lewis in Recommending Shareholders Vote “FOR” All Proposals Ahead of iBio’s Upcoming Annual Meeting
November 30, 2021 08:00 ET
|
iBio, Inc.
- iBio’s Board Urges Shareholders to Vote Today to Support Company’s Strategic Growth Plans - BRYAN, Texas, Nov. 30, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a...
Omicron Variant Underscores Need for New COVID Vaccine Candidates Like IBIO-202
November 29, 2021 08:45 ET
|
iBio, Inc.
- Global Reliance on Spike Protein-Based Vaccines May Create Public Health Risks - - Omicron’s Many Mutations Occur in Regions Outside Those of IBIO-202’s Nucleocapsid Antigen - - Company Expecting...
Leading Independent Proxy Advisory Firm, Glass Lewis, Recommends iBio Shareholders Vote “FOR” All Proposals Ahead of Annual Meeting
November 17, 2021 16:30 ET
|
iBio, Inc.
BRYAN, Texas, Nov. 17, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based...
iBio Reports Fiscal First Quarter 2022 Financial Results and Provides Corporate Update
November 15, 2021 16:05 ET
|
iBio, Inc.
- Adds First New Anti-cancer Target for Development in Partnership with RubrYc Therapeutics - - Initiates Research Collaboration with UT Southwestern to Study Anti-fibrotics in Oncology - -...
iBio Announces Collaboration with UT Southwestern to Investigate IBIO-100 in Solid Tumors
November 15, 2021 13:00 ET
|
iBio, Inc.
BRYAN, Texas, Nov. 15, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming...
iBio to Report Fiscal 2022 First Quarter Financial Results and Provide Corporate Update on Monday, November 15, 2021
November 08, 2021 16:30 ET
|
iBio, Inc.
BRYAN, Texas, Nov. 08, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based...